Decheng Capital

Decheng Capital

Forbes Tech

What Drives Newly Minted CRISPR Unicorn Mammoth Biosciences

$91,000,000 Post-IPO equity
GeekWire

Alpine raises $91M to fuel the Seattle biotech’s clinical trials for lupus and cancer

$150,000,000 Venture capital (Series D)
TechCrunch , Forbes Tech , MedCity News

Breakout “CRISPR platform” company Mammoth Biosciences is officially a unicorn

MedCity News

Invitae to buy health records startup Ciitizen for $325M 

Pulse 2.0

Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer

$112,000,000 Venture capital (Series B)
GeekWire

Seattle-based Shape Therapeutics raises $112M to develop RNA-editing and gene therapies

neurons.AI

Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of …

$70,000,000 Venture capital (Series D)
Pulse 2.0

Electronic Sequencing Platform GenapSys Raises $70 Million

neurons.AI

Sema4 to Participate in Upcoming Investor Conferences

neurons.AI

Sema4 to Participate in Upcoming Investor Conferences

$240,000,000 Post-IPO equity
PE HUB

Luckin Coffee to secure $240m: Reuters

Pulse 2.0

Invitae Stock Price: $48 Target By Oppenheimer

Pulse 2.0

Invitae Stock Price Increased Over 10% Pre-Market: Why It Happened

ChinaMoneyNetwork

China Tech Digest: Luckin Coffee Files For Bankruptcy In New York – China Money Network

Pulse 2.0

Luckin Coffee Stock Price Increased Over 120% This Past Week: Why It Happened

DealStreetAsia

China's Luckin Coffee to pay $180m penalty to settle accounting fraud charges

TechCrunch

China’s Luckin Coffee will pay $180 million to settle accounting fraud charges

Forbes Tech

Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein

DealStreetAsia

China regulators to penalise Luckin Coffee for accounting fraud

TechCrunch

Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH fundings through RADx program